Zacks Research Issues Positive Forecast for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $1.08 per share for the quarter, up from their prior estimate of $1.06. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.58 EPS, FY2025 earnings at $4.86 EPS, Q1 2026 earnings at $1.28 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.71 EPS and FY2026 earnings at $5.96 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million.

A number of other equities research analysts have also weighed in on HALO. Benchmark reissued a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Trading Up 0.3 %

NASDAQ HALO opened at $61.06 on Friday. Halozyme Therapeutics has a 1-year low of $37.73 and a 1-year high of $65.53. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The stock has a 50-day moving average of $56.50 and a 200-day moving average of $54.71. The firm has a market cap of $7.52 billion, a PE ratio of 17.80, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Institutional Trading of Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at $29,000. Smartleaf Asset Management LLC boosted its stake in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at $69,000. Finally, Parkside Financial Bank & Trust boosted its stake in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 322 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,697 shares of company stock valued at $1,754,451. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.